Janssen to use Ichor's TriGrid for HBV vaccine delivery
Executive Summary
Janssen Pharmaceuticals Inc. will use Ichor Medical Systems Inc.’s TriGrid electroporation technology as a delivery vehicle for its own DNA-based vaccines for chronic hepatitis B.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice